Advertisement

Chemotherapy in the Management of Pancreatic Cancer

  • Nai-Jung Chiang
  • Li-Tzong ChenEmail author
Chapter

Abstract

Pancreatic cancer is a highly malignant disease. Delay in diagnosis and occurrence of early dissemination make chemotherapy to be an evitable treatment option for nearly all patients of pancreatic cancer regardless the disease stage at time of inital diagnosis. The advance of medical therapy for pancreatic cancer has been slow, only very limited agnets have been approved to be beneficial for survival prolongation. In this article, we shall review the recent development of chemotherapy in patients with metastatic, locally advanced and resectable pancreatic cancer.

Keywords

Pancreatic Cancer Advanced Pancreatic Cancer Well Supportive Care Chemoradiation Therapy Metastatic Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    SEER Cancer Statistics Factsheets: Pancreas Cancer. National Cancer Institute. Bethesda. In: http://seer.cancer.gov/statfacts/html/pancreas.html.
  2. 2.
    National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: pancreatic adenocarcinoma (version 2). Fort Washington: National Comprehensive Cancer Network; 2015.Google Scholar
  3. 3.
    Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or met- astatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778–85.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson 3rd AB, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639–45.CrossRefPubMedGoogle Scholar
  13. 13.
    Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Rocha Lima CM, Green MR, Rotche R, Miller Jr WH, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–83.CrossRefPubMedGoogle Scholar
  15. 15.
    Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, et al. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III MAESTRO study. J Clin Oncol. 2016;34(Suppl 4S):abstr 193.Google Scholar
  18. 18.
    Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430–8.CrossRefPubMedGoogle Scholar
  19. 19.
    O’Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2016;27(6):1180. doi: 10.1093/annonc/mdw095.CrossRefPubMedGoogle Scholar
  20. 20.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617–22.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013;49:2633–42.CrossRefPubMedGoogle Scholar
  25. 25.
    Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12:256–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, et al. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015;26(6):1194–200.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, et al. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol. 2015;26(5):921–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–57.CrossRefPubMedGoogle Scholar
  29. 29.
    Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32:2423–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med. 2003;11:305–9.PubMedGoogle Scholar
  31. 31.
    Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004;29:e1–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60:2926–35.PubMedGoogle Scholar
  33. 33.
    Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI- 774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002;1:777–83.PubMedGoogle Scholar
  34. 34.
    Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy versus chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.CrossRefPubMedGoogle Scholar
  35. 35.
    Sinn M, Liersch T, Gellert K, Messmann H, Bechstein WO, Waldschmidt D, et al. CONKO-005: adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—a prospective randomized phase III study. J Clin Oncol. 2015;33(Suppl):abstr 4007.Google Scholar
  36. 36.
    ClinicalTrials.gov ID: NCT01013649, Gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that has been removed by surgery. In https://clinicaltrials.gov/.
  37. 37.
    Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol. 1999;17:2901–8.CrossRefPubMedGoogle Scholar
  38. 38.
    De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2000;28:2938–47.CrossRefGoogle Scholar
  39. 39.
    Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res. 1999;5:1189–96.PubMedGoogle Scholar
  40. 40.
    Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14:481–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 2005;23:1228–36.CrossRefPubMedGoogle Scholar
  42. 42.
    Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2012;31:23–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, et al. Phase II study of FOLFIRINOX for chemotherapy-na€ıve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014;105:1321–6.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ueno M, Ozaka M, Ishii H, Sato T, Ikeda M, Uesugi K, et al. Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. J Clin Oncol. 2016;34(Suppl):abstr 4111.Google Scholar
  45. 45.
    Von Hoff DD, Penny R, Shack S, Campbell E, Taverna D, Borad M,et al. Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents. J Clin Oncol. 2006;24(138s Suppl):abstr 3071.Google Scholar
  46. 46.
    Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–54.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial. Clin Cancer Res. 2015;21:4811–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 2014;63:974–83.CrossRefPubMedGoogle Scholar
  49. 49.
    Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, et al. SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts. Mol Cancer Ther. 2016;15(4):680–8.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77(3):595–603.CrossRefPubMedGoogle Scholar
  52. 52.
    Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705–10.CrossRefPubMedGoogle Scholar
  53. 53.
    Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil – an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751–5.Google Scholar
  55. 55.
    Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21:3409–14.CrossRefPubMedGoogle Scholar
  56. 56.
    Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.CrossRefPubMedGoogle Scholar
  57. 57.
    Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomized phase II study. Br J Cancer. 2009;101:1853–9.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, et al. Randomized phase III multi-Institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013;31:886–94.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer. 2002;95:933–40.CrossRefPubMedGoogle Scholar
  60. 60.
    Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867–72.CrossRefPubMedGoogle Scholar
  61. 61.
    Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trail. J Clin Oncol. 2011;29:4105–12.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–10.CrossRefPubMedGoogle Scholar
  63. 63.
    Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110:47–55.CrossRefPubMedGoogle Scholar
  64. 64.
    Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326–31.CrossRefPubMedGoogle Scholar
  65. 65.
    Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol. 2008;15:3521–31.CrossRefPubMedGoogle Scholar
  66. 66.
    Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol. 2008;26:1080–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, et al. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:809–16.CrossRefPubMedGoogle Scholar
  68. 68.
    Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, et al. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;66:527–34.CrossRefPubMedGoogle Scholar
  69. 69.
    Ch’ang HJ, Lin YL, Wang HP, Chang MC, Hsu CH, Tien YW, et al. Induction chemotherapy with gemcitabine, oxaliplatin and 5-FU/leucovorin followed by concomitant chemoradiation in patients with locally advanced pancreatic cancer: a Taiwan Cooperative Oncology Group phase II study. Int J Radiat Oncol Biol Phys. 2011;81:e749–57.CrossRefPubMedGoogle Scholar
  70. 70.
    Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, et al. The GOFURTGO study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. Br J Cancer. 2012;106:61–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29(22):3037–43.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Esnaola NF, Chaudhary UB, O’Brien P, Garrett-Mayer E, Camp ER, Thomas MB, et al. Phase 2 of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014;88:837–44.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.CrossRefPubMedGoogle Scholar
  75. 75.
    Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–15.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2004;358:1576–85.CrossRefGoogle Scholar
  77. 77.
    Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.CrossRefPubMedGoogle Scholar
  78. 78.
    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.CrossRefPubMedGoogle Scholar
  79. 79.
    Knaebel HP, Märten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]. BMC Cancer. 2005;5:37.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012;30:4077–83.CrossRefPubMedGoogle Scholar
  81. 81.
    Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil- based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–26.CrossRefPubMedGoogle Scholar
  82. 82.
    Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy following resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011;18:1319–26.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450–6.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, JASPAC 01 Study Group, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.CrossRefPubMedGoogle Scholar
  85. 85.
    Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016;34(Suppl):abstr LBA4006.Google Scholar
  86. 86.
    ClinicalTrials.gov ID: NCT01964430, a phase 3, multicenter, open-label, randomized study of nab-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma. In https://clinicaltrials.gov/.
  87. 87.
    ClinicalTrials.gov ID: NCT02172976, randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant fOLFIRINOX for resectable pancreas carcinoma. In https://clinicaltrials.gov/.
  88. 88.
    Boyd CA, Branch DW, Sheffield KM, Han Y, Kuo YF, Goodwin JS, et al. Hospital and medical care days in pancreatic cancer. Ann Surg Oncol. 2012;19:2435–42.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Enewold L, Harlan LC, Tucker T, McKenzie S. Pancreatic cancer in the USA: persistence of undertreatment and poor outcome. J Gastrointest Cancer. 2015;46:9–20.CrossRefPubMedGoogle Scholar
  90. 90.
    Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676–81.CrossRefPubMedGoogle Scholar
  91. 91.
    Oettle H, Lehman T. Gemcitabine-resistant pancreatic cancer: a second-line option. Lancet. 2016;387:507–8.CrossRefPubMedGoogle Scholar
  92. 92.
    Chiang NJ, Chang JY, Shan YS, Chen LT. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert Opin Pharmacother. 2016;17:1413–20.CrossRefPubMedGoogle Scholar
  93. 93.
    Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009;45:1589–96.CrossRefPubMedGoogle Scholar
  94. 94.
    Taïeb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol. 2007;18:498–503.CrossRefPubMedGoogle Scholar
  95. 95.
    Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009;101:1658–63.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016 Sep 12. pii: JCO685776. [Epub ahead of print].Google Scholar
  97. 97.
    Tsai CS, Park JW, Chen LT. Nanovector-based therapies in advanced pancreatic cancer. J Gastrointest Oncol. 2011;2:185–94.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Chang TC, Shiah HS, Yang CH, Cheng AL, Yeh CG, Chang JY, et al. Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579–86.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Chen LT, Shiah HS, Chao TY, et al. Phase I study of liposome irinotecan (PEP02) in combination with weekly infusion of 5-FU/LV in advanced solid tumors. ASCO Meet Abstr. 2010;28:e13024.Google Scholar
  100. 100.
    Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational phase 2 study of nanoliposomal irinotecan (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013;109:920–5.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Chibaudel B, Maindrault-Goebel F, Bachet JB, Louvet C, Khalil A, Dupuis O, et al. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med. 2016; doi: 10.1002/cam4.635.PubMedPubMedCentralGoogle Scholar
  102. 102.
    ClinicalTrials.gov ID: NCT02697058, phase II randomized study of BAX2398 in combination with 5-fluorouracil and calcium levofolinate in Japanese patients with metastatic pancreatic cancer, which progressed or recurred after prior gemcitabine-based therapy. In https://clinicaltrials.gov/.
  103. 103.
    Chung VM, McDonough SL, Phillip PA, Cardin DB, Wang-Gillam A, Hui L, et al. SWOG S1115: randomized phase II trial of selumetinib (AZD6624; ARRY 142886) hydrogen sulfate (NSC-748727) and MEK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients with metastatic pancreatic cancer. J Clin Oncol. 2015;33(Suppl): abstr 4119.Google Scholar
  104. 104.
    Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade 3rd SM, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33:4039–47.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Hurwitz H, Garrett WM, Clark J, Brill KJ, Dawkins FW, Hidalgo M, et al. JANUS 1: a phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer after failure or intolerance of first-line chemotherapy. J Clin Oncol. 2015;33(Suppl):abstr TPS4147.Google Scholar
  106. 106.
    O’Reilly EM, Walker C, Clark J, Brill KJ, Dawkins FW, Bendell JC, et al. JANUS 2: a phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer who failed or were intolerant to first-line chemotherapy. J Clin Oncol. 2015;33(Suppl):abstr TPS4146.Google Scholar
  107. 107.
    ClinicalTrials.gov Identifier: NCT01956812, an international, multi-center, double-blind, randomized, phase III trial of 90Y-clivatuzumab tetraxetan plus low-dose gemcitabine versus placebo plus low-dose gemcitabine in patients with metastatic (stage IV) pancreatic adenocarcinoma who received at least two prior treatments (PANCRIT-1). In https://clinicaltrials.gov/.
  108. 108.
    Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer. 2015;112:1428–34.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Mizuno N, Yamao K, Komatsu Y, Munakata M, Ishiguro A, Yamaguchi T, et al. Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer. J Clin Oncol. 2012;30(Suppl 34):abstr 263.Google Scholar
  110. 110.
    Liu TW, Chen LT. S-1 and leucovorin for gastric cancer: how far can it go? (Commentary). Lancet Oncol. 2016;17(1):12–4.CrossRefPubMedGoogle Scholar
  111. 111.
    Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, et al. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Ann Oncol. 2016;27:502–8.CrossRefPubMedGoogle Scholar
  112. 112.
    JapicCTI-No: JapicCTI-132172, a phase III trial comparing the overall survival of TAS-118 (a combo of S-1 and leucovorin) and S-1 in 600 patients with gemcitabine only-refractory advanced pancreatic cancer. In http://www.clinicaltrials.jp/user/.
  113. 113.
    Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113(7):989–95.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Vivaldi C, Fornaro L, Caparello C, Falcone A, Vasile E. Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort’. Br J Cancer. 2016;114(11):e8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.National Institute of Cancer Research, National Health Research InstitutesTainanTaiwan

Personalised recommendations